Conflict of interest None. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. D‘Amico G. The PF-02341066 chemical structure commonest glomerulonephrites in the world. IgA nephropathy. Q J Med. 1987;64:709–27. 2. Levy M, see more Berger J. Worldwide prospective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–7.PubMed 3. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research group on progressive

renal diseases. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef 4. Donadio JV, Grade JP. IgA nephropathy. N Engl J Med. 2002;347:738–48. 5. Strippoli GF, Manno

C, Schena FP. An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis. 2003;41:1129–39.PubMedCrossRef 6. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Cochrane Database Syst Rev. 2003;CD003965. 7. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. MK5108 supplier 2003;63:1861–7.PubMedCrossRef 8. Pozzi C, Bolasco PG, Fogazzi GB, Andulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy. A randomized controlled trial. Lancet. 1999;353:883–7.PubMedCrossRef 9. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy. Long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.PubMedCrossRef 10. Special Study Group (IgA Nephropathy) on Progressive Glomerular Disease. Clinical guideline

for immunoglobulin A (IgA) nephropathy in Japan, 3rd version. Jpn J Nephrol. 2011;53(2):123–35. 11. Kobayashi Y, Fujii K, Hiki Y, Tateno S. Steroid Ribonucleotide reductase therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med. 1986;234:935–43. 12. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significanctly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef 13. Akagi H, Fukushima K, Kosaka M, Doi A, Okano M, Kariya S, et al. A 10-year retrospective case–control study for IgA nephropathy after tonsillectomy. Int Congr Ser. 2003;1257:147–50. 14. Katafuchi R, Ninomiya T, Mizumasa T, Ikeda K, Kumagai H, Nagata M, et al. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transplant. 2008;23:3915–20.PubMedCrossRef”
“Introduction Focal segmental glomerulosclerosis (FSGS) may present with rapid development of systemic edema, often manifesting nephrotic syndrome (NS), microscopic hematuria, and hypertension [1].